Celgene oncology head on ASCO, Revlimid, and the rising value of triplet combinations

26 May 2017

Speaking with The Pharma Letter ahead of the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), Michael Pehl says that “we are really excited about the event - we have a really broad range of clinical data.”

Mr Pehl, who has been president of Celgene’s (Nasdaq: CELG) global hematology amd oncology division for about a year, has been with the New Jersey-based firm for more than a decade.

Before joining the company, he spent 14 years at Amgen (Nasdaq: AMGN), holding various positions in oncology, rheumatology and nephrology, both in Germany and at the regional level.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK